Mnjoyan Zakar, Yoon Donghoon, Li Jun, Delhommeau François, Afshar-Kharghan Vahid
Haematologica. 2006 Mar;91(3):411-2. Epub 2006 Feb 17.
JAK2(V617F)an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2(V617F) on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2(V617F) increased both PRV-1 protein and mRNA levels in murine myeloid cells. A JAK2 inhibitor eliminated the V617F-induced increase in PRV-1 expression.
JAK2（V617F）是JAK2的一种获得性突变，存在于大多数真性红细胞增多症患者中，在其他骨髓增殖性疾病患者中出现的比例较低。我们使用体外模型分析了JAK2（V617F）对真性红细胞增多症1（PRV-1）表达的影响。与野生型JAK2相比，JAK2（V617F）的存在增加了小鼠骨髓细胞中PRV-1蛋白和mRNA水平。一种JAK2抑制剂消除了V617F诱导的PRV-1表达增加。
